• costs of outside consultants, including their fees, stock compensation, and related travel expenses; • expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, and other vendors that conduct our clinical trials and preclinical activities; • costs of acquiring, developing, and manufacturing clinical trial materials, and lab supplies; • cos

filing / Aug 6, 2026 / receipt

as a public company, including compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs; travel expenses; and facility-related expenses, which include depreciation costs and allocated expenses for rent and maintenance of facilities.

filing / Aug 6, 2026 / receipt

• our headcount growth and associated costs if and as we expand our business operations and our research and development activities; and

filing / Aug 6, 2026 / receipt

If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

filing / Aug 6, 2026 / receipt

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

filing / Aug 6, 2026 / receipt

If there are unforeseen expenses associated with such realignments in our business strategies, and we incur unanticipated charges or liabilities, we may not be able to effectively realize the expected cost savings or other benefits of such actions,

filing / Aug 6, 2026 / receipt

• costs of outside consultants, including their fees, stock compensation, and related travel expenses; • expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, and other vendors that conduct our clinical trials and preclinical activities; • costs of acquiring, developing, and manufacturing clinical trial materials, and lab supplies; • cos

filing / May 5, 2026 / receipt

as a public company, including compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs; travel expenses; and facility-related expenses, which include depreciation costs and allocated expenses for rent and maintenance of facilities.

filing / May 5, 2026 / receipt

• our headcount growth and associated costs if and as we expand our business operations and our research and development activities; and

filing / May 5, 2026 / receipt

If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

filing / May 5, 2026 / receipt

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

filing / May 5, 2026 / receipt

If there are unforeseen expenses associated with such realignments in our business strategies, and we incur unanticipated charges or liabilities, we may not be able to effectively realize the expected cost savings or other benefits of such actions, which could have adverse effects on our business, operating results, and financial condition.

filing / May 5, 2026 / receipt